What happens to my weight when I stop a GLP-1 agonist?

Published August 19, 2026

Many patients stop a GLP-1 agonist without a plan in place. This can occur for various reasons. Some people run out or lose access to the medication, others get priced out and some decide they are finished once they’ve hit a goal. Often no one has walked them through what happens after they stop and that is where the weight can return.

If you have lost meaningful weight on semaglutide or tirzepatide (Wegovy or Zepbound), discontinuation is a fair thing to worry about. Here is what the data shows happens after you stop, why it happens and what you can do to protect your progress.

What the research shows

Two of the largest withdrawal trials give us clear numbers.

In the STEP 1 extension trial, adults taking semaglutide 2.4 mg with lifestyle support lost an average of 17.3% of their body weight over 68 weeks . One year after stopping both the medication and that support, the participants regained about two-thirds of the weight that they had lost.

The SURMOUNT-4 study tested tirzepatide in a similar way. Participants were started on tirzepatide and they lost on average 20.9% of their body weight, during the first 36-weeks. After 36 weeks, half of them continued the medication while the other half were switched to placebo. Over the next year, the group that continued tirzepatide lost an additional 5.5% body weight, while the placebo group regained 14% of their body weight. At the end, the participants who stayed on treatment lost a total of 25.3% body weight while those who stopped it lost 9.9%. A subsequent analysis found that participants who discontinued tirzepatide after 36 weeks also experienced a reversal of their cardiometabolic improvements within a year.

Why the weight comes back

Obesity is a chronic metabolic condition, similar to high blood pressure or type 2 diabetes. A GLP-1 agonist works by acting on the hormones that regulate appetite and fullness, while you take the medication. When the medication leaves your system, the underlying signals gradually return; hunger climbs, fullness fades sooner and your body works to pull you back toward its prior set point.

Weight regain after stopping the medication reflects the disease reasserting itself. Discipline has very little to do with it. The studies showed that cardiometabolic improvements drifted back too. As the weight returned, blood sugar, blood pressure and cholesterol moved back toward where they started.

This is why framing a GLP-1 agonist as a temporary fix sets many people up for disappointment. The medication manages an ongoing process for as long as you take it.

What changes the outcome

The decision to stop a GLP-1 medication is best made with clinical supervision.

In my practice, a maintenance plan starts with deciding together whether you come off at all. For most patients, the right move is finding a lower maintenance dose that maintains their progress. For others a full taper makes sense. That call depends more on your history and your response to the dose adjustments, rather than a hard and fast rule.

When we do reduce or discontinue the medication, we taper with intention and watch your weight and metabolic markers as we go, so we can adjust before weight regain builds momentum. Protecting muscle is part of the same plan, because rapid loss and regain cycles cost lean mass. Adequate protein and resistance training preserve the muscle that keeps your metabolism and strength intact, which matters even more if you lower your dose or come off entirely.

Through all of it, we keep your metabolic health in view and not just the scale. Your hemoglobin A1C, lipids and blood pressure also tell us whether your underlying health improvements are being sustained.

Who should be thinking about this now

Some patients need a plan sooner than they expect. If you are taking a compounded GLP-1 agonist and no one has talked to you about what happens next, this applies to you. Access to compounded medication is tightening; studies suggest that being forced off the medication suddenly puts you at risk of weight regain. It also applies if you are close to your goal weight and assuming the loss will be sustained after stopping, or if you are facing medication interruption due to cost, limited supply or a change in insurance coverage.

The bottom line

Weight regain that follows GLP-1 agonist discontinuation is well-documented, but it can be mitigated with close follow-up and clinical supervision. Planning the taper alongside a physician who monitors your progress, gives you a better chance of preventing regain.

If you are on a GLP-1 agonist without a maintenance plan or you are considering starting and want to understand the long game first, let's talk. Book a discovery call and we will outline what the process would look like for you.

This article is for education purposes and is not medical advice. Do not start, stop or change any medication without consulting your physician.